Pharmaceuticals, Biotechnology & Life Sciences

Amgen’s biotech strategy fuels growth—expanding biologics, scaling manufacturing, and advancing clinical trials to strengthen market leadership and investor confidence.

Assertio Holdings faces a double‑edged future: potential Russell Microcap upgrade could lift shares, while a new shareholder‑rights investigation may reshape its governance and capital structure.

Hansa Biopharma’s Phase III ConfIdeS results on the enzyme imflidas will be presented as a late‑breaking abstract at the American Transplant Congress, potentially advancing kidney transplant therapy and regulatory prospects.

Hemostemix Inc. battles financial turbulence while pioneering blood‑derived cell therapies for severe medical disorders, sparking investor debate over its future viability.

Telix Pharmaceuticals’ innovative cancer‑treating tech faces sharp stock dips and a negative P/E—investors should weigh this technical downtrend with broader market research.

Explore aTyr Pharma’s biotech journey—protein therapeutics, market challenges, and future potential—while staying updated on its Nasdaq performance.

Shield Therapeutics PLC is reshaping secondary‑care pharma with late‑stage oral iron‑deficiency anemia and phosphate binder drugs, driving investor confidence and patient hope.

Bruker’s 2026 annual meeting confirms new directors, executive pay votes, and PWC’s audit role, underscoring solid governance and future growth in life‑science tools.

Discover iX Biopharma’s breakthrough sublingual ketamine and buprenorphine wafer therapies for acute pain, plus nutraceuticals and lab services driving growth in Singapore and beyond.

Projected Leqembi sales hit ¥300 billion in FY 2029, showing strong growth for Eisai’s Alzheimer’s therapy and boosting its market value.